Approaches to vancomycin-resistant enterococci
- 1 December 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 17 (6), 541-547
- https://doi.org/10.1097/00001432-200412000-00006
Abstract
This article reviews recent publications regarding new antimicrobial drugs for the treatment of vancomycin-resistant enterococci. Newer drugs against vancomycin-resistant enterococci are now available or will soon be available. Quinupristin-dalfopristin, a streptogramin, and linezolid, an oxazolidinone, are effective and safe but only bacteriostatic against enterococi. Bacterial isolates resistant to either antibiotic have been described. Daptomycin, a lipopeptide antimicrobial, has good in-vitro bactericidal activity against enterococci, but very limited clinical data exist regarding the treatment of serious enterococcal infection with this compound. Ramoplanin, the first glycolipodepsipeptide antimicrobial in clinical trials, is not systemically absorbed after oral administration, and is being evaluated for the prevention of bloodstream infection in patients colonized with vancomycin-resistant enterococci. Oritavancin and dalbavancin (both glycopeptides) and tigecycline (a monocycline derivative) are being evaluated in phase II and III trials and are not yet commercially available. Treatment of vancomycin-resistant enterococci continues to be problematical although these new drugs offer some hope. The rational use of antibiotics, strict guidelines for the use of new compounds, and adherence to infection control practices continue to be essential components of the management of vancomycin-resistant enterococci colonization and infection.Keywords
This publication has 90 references indexed in Scilit:
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003American Journal of Infection Control, 2003
- Clinical Outcomes for Patients with Bacteremia Caused by Vancomycin?Resistant Enterococcus in a Level 1 Trauma CenterClinical Infectious Diseases, 2002
- Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter StudyAnnals of Internal Medicine, 2001
- Enterococcus faecium BacteremiaArchives of Internal Medicine, 1998
- Management of infections due to resistant enterococci: a review of therapeutic optionsJournal of Antimicrobial Chemotherapy, 1997
- Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcusJournal of Antimicrobial Chemotherapy, 1997
- Vancomycin-Resistant Enterococcal Bacteremia: Natural History and Attributable MortalityClinical Infectious Diseases, 1996
- Effects of Cigarette Smoking on Lung Function in Adolescent Boys and GirlsNew England Journal of Medicine, 1996
- Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus FaeciumNew England Journal of Medicine, 1988
- VANCOMYCIN-RESISTANT ENTEROCOCCIThe Lancet, 1988